A Method to Generate Novel Bioactive Molecules
- 详细技术说明
- UC San Diego inventors have invented a very general method to design and create new compounds with anti-bacterial, anti-fungal, anti-cancer, or other bioactive properties. Different from the existing art, where the biological effect of a compound must be determined, this invention allows for compounds to be designed and created with these effects known a priori. For example, this shortcoming, which the current invention overcomes, is part of the existing art being applied to anti-bacterial synthesis—such as mutational biosynthesis, genetic engineering, structure-based drug design, or interrogation of novel natural products.Slide Show Presentation
- *Abstract
-
None
- *IP Issue Date
- Jul 14, 2015
- *Principal Investigation
-
Name: Pep Charusanti
Department:
Name: Bernhard Palsson
Department:
- 附加资料
- Patent Number: US20130211100A1
Application Number: US13825792A
Inventor: Palsson, Bernhard | Charusanti, Pep
Priority Date: 29 Oct 2010
Priority Number: US20130211100A1
Application Date: 1 May 2013
Publication Date: 15 Aug 2013
IPC Current: C12Q000118 | C12N000120
US Class: 548453 | 43500611 | 435032 | 4352535
Title: Method to Generate Novel Bioactive Molecules
Usefulness: Method to Generate Novel Bioactive Molecules
Summary: The methods are useful for identifying a bioactive compound in a culture; and for identifying a genomic mutation in an organism (all claimed).
Novelty: Identifying a bioactive compound in a culture comprises co-culturing two or more organisms, detecting inhibition of growth of the target organisms, and detecting the presence of one or more bioactive compounds in the co-culture
- 主要类别
- 生物医学
- 细分类别
- DNA /基因工程
- 申请号码
- 9080199
- 其他
-
State Of Development
Experimental work to create a positive bioassay has been completed and the invention is already being applied to the creation of novel anti-bacterial agents.
Other Information
Access the recommendation on F1000 Prime

Tech ID/UC Case
19978/2008-230-0
Related Cases
2008-230-0
- 国家/地区
- 美国
欲了解更多信息,请点击 这里
